Lexeo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Revenue	0	0.65	1.66
Revenue Growth (YoY)	-	-60.53%	-
Gross Profit	0	0.65	1.66
Selling, General & Admin	15.38	12	7.17
Research & Development	53.13	49.16	45.12
Operating Expenses	68.51	61.16	52.29
Operating Income	-68.51	-60.51	-50.64
Interest Expense / Income	0.21	0.09	0
Other Expense / Income	-2.32	-1.32	-0.02
Pretax Income	-66.39	-59.28	-50.62
Net Income	-66.39	-59.28	-50.62
Shares Outstanding (Basic)	5	2	2
Shares Outstanding (Diluted)	5	2	2
Shares Change	228.42%	5.00%	-
EPS (Basic)	-12.40	-36.36	-32.60
EPS (Diluted)	-12.40	-36.36	-32.60
Free Cash Flow	-59.61	-55.23	-44.37
Free Cash Flow Per Share	-11.13	-33.88	-28.58
Gross Margin	-	100.00%	100.00%
Operating Margin	-	-9252.14%	-3055.94%
Profit Margin	-	-9063.76%	-3055.04%
Free Cash Flow Margin	-	-8445.26%	-2677.73%
EBITDA	-64.35	-58.04	-50.61
EBITDA Margin	-	-8874.77%	-3054.25%
Depreciation & Amortization	1.84	1.15	0.01
EBIT	-66.19	-59.19	-50.62
EBIT Margin	-	-9049.85%	-3055.04%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).